General literature
PROTACs Developed with U. of Dundee Boost Boehringer Ingelheim's Cancer Pipeline

Philippidis A.

Gen Edge 2019, VOL. 1, NO. 1.

DOI
Success examples
The inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approach

Agosile O. O., Njoku P. C., Oduwe U., Aremu A. J., Fajobi S. J., Akachukwu S. O., Adebisi A. R., Abolaji A. O., Omirin E. S.

Research Square 2023, PREPRINT (Version 1).

KRAS switch I/II pocket inhibitor
DOI
Success examples
Novel GLP-1 secretagogues as neuroprotective agents for retinal neurodegenerative diseases

Powell F. L., Thomas S., Martin P. M.

Invest. Ophthalmol. Vis. Sci. 2023, 64(8):1842.

GPR142 Agonist
DOI
Success examples
A cathepsin C-like protease mediates the post-translation modification of Toxoplasma gondii secretory proteins for optimal invasion and egress

Thornton L. B., Key M., Micchelli C., Stasic A. J., Kwain S., Floyd K., Moreno S. N. J., Dominy B. N., Whitehead D. C., Dou Z.

mBio 2023, e0017423. Epub 2023 Jun 16.

DPAP1 Inhibitor
DOI
PubMed
Success examples
Canonical BAF complex activity shapes the enhancer landscape that licenses CD8+ T cell effector and memory fates

McDonald B., Chick B. Y., Ahmed N. S., Burns M., Ma S., Casillas E., Chen D., Mann T. H., O'Connor C., Hah N., Hargreaves D. C., Kaech S. M.

Immunity 2023, 56(6):1303-1319.e5.

SMARCA2/4 PROTAC
DOI
PubMed
Success examples
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Kim D., Herdeis L., Rudolph D., Zhao Y., Böttcher J., Vides A., Ayala-Santos C. I., Pourfarjam Y., Cuevas-Navarro A., Xue J. Y., Mantoulidis A., Bröker J., Wunberg T., Schaaf O., Popow J., Wolkerstorfer B., Kropatsch K. G., Qu R., de Stanchina E., Sang B., Li C., McConnell D. B., Kraut N., Lito P.

Nature 2023, 619(7968):160-166.

KRAS switch I/II pocket inhibitor
DOI
PubMed